Dr. Laura Ann Kalayjian, MD

Dr. Kalayjian practices at Los Angeles General Medical Center in Los Angeles, California, part of County of Los Angeles.

Dr. Kalayjian's NPI, 1205877917, was assigned on June 10, 2006. Dr. Kalayjian graduated from UMass Chan Medical School in 1995. Dr. Kalayjian holds California license A61593.

Dr. Kalayjian's primary practice is Los Angeles General Medical Center, at 2051 Marengo St, Room C2K100, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 226-2800.

Dr. Kalayjian's primary practice is Los Angeles General Medical Center in Los Angeles, California, part of County of Los Angeles. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Kalayjian to 1 more group practice or clinic, named with a free account. Dr. Kalayjian's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalayjian practices, 2 sites in all. Vendor and product names are available with a free account.

Epilepsy is Dr. Kalayjian's primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dr. Kalayjian is board certified in clinical neurophysiology by the American Board of Psychiatry and Neurology. Dr. Kalayjian is licensed in California.

Dmand AI lists cerebrovascular disease, dementia, epilepsy, neck pain and spine problems and seizures among the conditions Dr. Kalayjian treats.

CMS data shows 312 Medicare services from Dr. Kalayjian across 5 procedure codes in 2024, for 158 Medicare patients. Medicare paid $22,147 for them.

CMS counts 158 Medicare patients who saw Dr. Kalayjian in 2024. The largest group is under 65, with 66 patients. 66% of them have high blood pressure, and 65% have high cholesterol. 63% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalayjian's median patient age at 52, with 50% women.

In 2024, Dr. Kalayjian wrote 1,874 Medicare Part D claims for 118 patients. 73% of them were for generic drugs. CMS names the drug for 1,736 of them, across 42 drugs with 11 or more claims each, at $987,146 in total drug cost. In 2023, CMS named 1,248 claims across 38 drugs.

Dmand AI links 13 papers to Dr. Kalayjian, published from 2010 to 2022. 2011 was the busiest year, with 3. The most frequent topics are Epilepsy. Dr. Kalayjian's most frequent co-authors are Kimford Jay Meador, MD, Page B. Pennell, MD and Joyce Liporace, MD.

Dmand AI links Dr. Kalayjian to 1 clinical trial. Conditions studied include Epilepsy and Brain Diseases.

CMS Open Payments shows 63 general payments to Dr. Kalayjian from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. LivaNova USA, Inc. paid the most, $424.

Dr. Kalayjian graduated from UMass Chan Medical School in 1995.

Dr. Kalayjian is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.